29 January 2025
This announcement contains
inside information as stipulated under the UK version of the Market
Abuse Regulation 596/2014 which is part of English Law by virtue of
the European (Withdrawal) Act 2018, as amended. On publication of
this announcement via a regulatory information service, this
information is considered to be in the public
domain.
BEXIMCO PHARMACEUTICALS
LIMITED
Half Year Results
2024-25
Beximco Pharmaceuticals Limited
("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI
No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic
pharmaceutical products and active pharmaceutical ingredients,
today announces its unaudited financial results for the six months
ended 31 December 2024.
Financial Highlights
Half year financial highlights
· Net
sales increased 8.8% to Bangladesh Taka ("BDT") 24,013.4m/£ 161.5m
(2023-24: BDT22,063.6m / £ 157.7m)
o Domestic sales increased 7.4% to BDT 22,262.3m / £ 149.7m
(2023-24: BDT 20,733.4m / £148.2m)
o Export sales increased 31.6% to BDT 1,751.1m / £ 11.8m
(2023-24: BDT 1,330.2m / £9.5m)
· Profit
after tax increased 17.5% to BDT 3,535.0m/£ 23.8m (2023-24: BDT
3,008.2m / £21.5m)
Second quarter financial highlights
· Net
sales increased 12.8% to BDT 12,299.6m / £ 82.7m (2023-24: BDT
10,904.2m / £77.9m)
· Profit
after tax increased 27.9% to BDT 1,843.1m / £ 12.4m (2023-24: BDT
1,440.8m / £10.3m)
Operational highlights
· Launched four new products in Bangladesh market
· Completed 28 new registrations of 27 products across 5
countries
· Commenced export to four new countries - Cuba, Malta, Qatar
and Angola
Beximco Pharma Managing Director, Iqbal Ahmed,
commented:
"We're pleased to announce Beximco Pharma's second quarter and
half year results today, demonstrating strong, profitable growth
despite persisting macro-economic challenges. We have launched four
new products domestically while we have experienced further growth
internationally through new product registrations and expansion
into new export countries. We look forward to building on this
momentum into the second half of the year and continue to provide
vital medicine to patients across the world."
The half yearly accounts can be
viewed at the Company's website: www.beximcopharma.com
(Exchange rates of £1=Taka 148.6917
for 31 December 2024 and £1=Taka 139.9145 for 31 December 2023 have
been used in this announcement.)
This announcement is available in its entirety at http://www.rns-pdf.londonstockexchange.com/rns/0191V_1-2025-1-28.pdf
For further information please
visit www.beximcopharma.com or
enquire to:
Beximco
Pharma
S M Rabbur Reza, Chief Operating
Officer
Tel: +880 2 58611001, Ext.
20111
Mohammad Ali Nawaz, Chief Financial
Officer
Tel: +880 2 58611001, Ext.
20030
Mohammad Asad Ullah, FCS
Executive Director & Company
Secretary
Tel: +880 2 41060531, Ext.
10140
SPARK Advisory Partners Limited
(Nominated
Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP
(Broker)
Matthew
Johnson
Tel: +44 (0) 20 3470
0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Sam
Purewal
Tel: +44 (0)20 3727
1000
Notes to
Editors
About Beximco Pharmaceuticals
Limited
Beximco Pharma is a leading manufacturer and exporter
of medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 6,000
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the region.
